31 related articles for article (PubMed ID: 24283754)
1. An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.
Prinz LF; Riet T; Neureuther DF; Lennartz S; Chrobok D; Hübbe H; Uhl G; Riet N; Hofmann P; Hösel M; Simon AG; Tetenborg L; Segbers P; Shimono J; Gödel P; Balke-Want H; Flümann R; Knittel G; Reinhardt HC; Scheid C; Büttner R; Chapuy B; Ullrich RT; Hallek M; Chmielewski MM
Cell Rep Med; 2024 Feb; 5(2):101421. PubMed ID: 38340727
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells.
Le Floch AC; Rouvière MS; Salem N; Ben Amara A; Orlanducci F; Vey N; Gorvel L; Chretien AS; Olive D
Cells; 2023 Jun; 12(13):. PubMed ID: 37443727
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia.
Jiménez-Morales S; Aranda-Uribe IS; Pérez-Amado CJ; Ramírez-Bello J; Hidalgo-Miranda A
Front Immunol; 2021; 12():737340. PubMed ID: 34867958
[TBL] [Abstract][Full Text] [Related]
4. sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection.
Jubel JM; Randau TM; Becker-Gotot J; Scheidt S; Wimmer MD; Kohlhof H; Burger C; Wirtz DC; Schildberg FA
Front Immunol; 2021; 12():687065. PubMed ID: 34421900
[TBL] [Abstract][Full Text] [Related]
5. Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma.
Liu J; Tian X; Wang Y; Kang X; Song W
BMC Immunol; 2021 May; 22(1):33. PubMed ID: 34006227
[TBL] [Abstract][Full Text] [Related]
6. Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies.
Lin S; Cheng L; Ye W; Li S; Zheng D; Qin L; Wu Q; Long Y; Lin S; Wang S; Huang G; Li P; Yao Y; Sun X
Front Immunol; 2021; 12():642528. PubMed ID: 33868277
[TBL] [Abstract][Full Text] [Related]
7. A model of seven immune checkpoint-related genes predicting overall survival for head and neck squamous cell carcinoma.
Song D; Tian J; Han X; Li X
Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3467-3477. PubMed ID: 33449165
[TBL] [Abstract][Full Text] [Related]
8. Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.
Chakrabarti R; Kapse B; Mukherjee G
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1160. PubMed ID: 32721130
[TBL] [Abstract][Full Text] [Related]
9. Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia.
Hathorn KE; Luskin MR; Caton MT; DeAngelo DJ; Saltzman JR
ACG Case Rep J; 2019 Aug; 6(8):e00207. PubMed ID: 31737733
[TBL] [Abstract][Full Text] [Related]
10. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
11. Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).
Ishii K; Barrett AJ
Ther Adv Hematol; 2016 Feb; 7(1):17-39. PubMed ID: 26834952
[TBL] [Abstract][Full Text] [Related]
12. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Knaus HA; Kanakry CG; Luznik L; Gojo I
Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia.
Mansour A; Elkhodary T; Darwish A; Mabed M
Leuk Lymphoma; 2014 Sep; 55(9):2120-4. PubMed ID: 24283754
[TBL] [Abstract][Full Text] [Related]
15. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schütz C; Inselmann S; Saussele S; Dietz CT; Mu Ller MC; Eigendorff E; Brendel CA; Metzelder SK; Bru Mmendorf TH; Waller C; Dengler J; Goebeler ME; Herbst R; Freunek G; Hanzel S; Illmer T; Wang Y; Lange T; Finkernagel F; Hehlmann R; Huber M; Neubauer A; Hochhaus A; Guilhot J; Xavier Mahon F; Pfirrmann M; Burchert A
Leukemia; 2017 Apr; 31(4):829-836. PubMed ID: 28074067
[TBL] [Abstract][Full Text] [Related]
16. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
[TBL] [Abstract][Full Text] [Related]
17. A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression.
Simone R; Tenca C; Fais F; Luciani M; De Rossi G; Pesce G; Bagnasco M; Saverino D
PLoS One; 2012; 7(9):e44654. PubMed ID: 23049754
[TBL] [Abstract][Full Text] [Related]
18. The soluble CTLA-4 receptor and its role in autoimmune diseases: an update.
Saverino D; Simone R; Bagnasco M; Pesce G
Auto Immun Highlights; 2010 Nov; 1(2):73-81. PubMed ID: 26000110
[TBL] [Abstract][Full Text] [Related]
19. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
